These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 24706642)

  • 41. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.
    de Rooij MF; Kuil A; Kater AP; Kersten MJ; Pals ST; Spaargaren M
    Blood; 2015 Apr; 125(14):2306-9. PubMed ID: 25838279
    [No Abstract]   [Full Text] [Related]  

  • 42. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 43. Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.
    Brown JR; Zelenetz A; Furman R; Lamanna N; Mato A; Montillo M; O'Brien S; Dubowy R; Gu L; Munugalavadla V; Robak T; Hillmen P
    Leukemia; 2020 Dec; 34(12):3404-3407. PubMed ID: 32655145
    [No Abstract]   [Full Text] [Related]  

  • 44. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The use of ibrutinib in chronic lymphocytic leukemia.
    Damon LE
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):154-6. PubMed ID: 27058026
    [No Abstract]   [Full Text] [Related]  

  • 46. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
    Visentin A; Imbergamo S; Scomazzon E; Pravato S; Frezzato F; Bonaldi L; Pizzi M; Vio S; Gregianin M; Burei M; Facco M; Semenzato G; Piazza F; Trentin L
    Br J Haematol; 2019 Apr; 185(1):193-197. PubMed ID: 29974955
    [No Abstract]   [Full Text] [Related]  

  • 48. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
    Brown JR
    Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clonal dynamics in chronic lymphocytic leukemia.
    Gutierrez C; Wu CJ
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):466-475. PubMed ID: 31808879
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Soumerai JD; Ni A; Xing G; Huang J; Furman RR; Jones J; Sharman JP; Hallek M; Adewoye AH; Dubowy R; Dreiling L; Zelenetz AD
    Leuk Lymphoma; 2019 Jun; 60(6):1438-1446. PubMed ID: 30407886
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment.
    Gaidano G; Rossi D
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):329-337. PubMed ID: 29222275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?
    Pospisilova S; Sutton LA; Malcikova J; Tausch E; Rossi D; Montserrat E; Moreno C; Stamatopoulos K; Gaidano G; Rosenquist R; Ghia P;
    Haematologica; 2016 Mar; 101(3):263-5. PubMed ID: 26928246
    [No Abstract]   [Full Text] [Related]  

  • 53. Speed bumps on the road to a chemotherapy-free world for lymphoma patients.
    Cheson BD
    Blood; 2016 Jul; 128(3):325-30. PubMed ID: 27222479
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ibrutinib, obinutuzumab, idelalisib, and beyond: review of novel and evolving therapies for chronic lymphocytic leukemia.
    Chung C; Lee R
    Pharmacotherapy; 2014 Dec; 34(12):1298-316. PubMed ID: 25355689
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.
    Reda G; Cassin R; Artoni A; Fattizzo B; Lecchi A; La Marca S; Bucciarelli P; Levati GV; Peyvandi F; Cortelezzi A
    Br J Haematol; 2018 Dec; 183(5):825-828. PubMed ID: 29315493
    [No Abstract]   [Full Text] [Related]  

  • 56. Life after ibrutinib? A new unmet need in CLL.
    Pinilla-Ibarz J; Chavez JC
    Blood; 2015 Mar; 125(13):2013-4. PubMed ID: 25814485
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3Kδ inhibition.
    Pepper C; Buggins AG; Jones CH; Walsby EJ; Forconi F; Pratt G; Devereux S; Stevenson FK; Fegan C
    Leukemia; 2015 Mar; 29(3):744-7. PubMed ID: 25349153
    [No Abstract]   [Full Text] [Related]  

  • 58. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
    Molica S
    BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Chronic lymphatic leukemia].
    Bergmann M; Wendtner CM
    Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted therapy in the treatment of chronic lymphocytic leukemia: facts, shortcomings and hopes for the future.
    Molica S
    Expert Rev Hematol; 2017 May; 10(5):425-432. PubMed ID: 28349723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.